These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 16120047)

  • 1. Epidermal growth factor inhibition in solid tumours.
    Ganti AK; Potti A
    Expert Opin Biol Ther; 2005 Sep; 5(9):1165-74. PubMed ID: 16120047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
    Harichand-Herdt S; Ramalingam SS
    Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR pathway in advanced non-small cell lung cancer.
    Merlo V; Longo M; Novello S; Scagliotti GV
    Front Biosci (Schol Ed); 2011 Jan; 3(2):501-17. PubMed ID: 21196393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapy in advanced non-small-cell lung cancer.
    Gettinger S
    Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
    Blackledge G; Averbuch S
    Br J Cancer; 2004 Feb; 90(3):566-72. PubMed ID: 14760365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
    Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
    Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical treatment of non-small-cell lung cancer.
    Buter J; Giaccone G
    Ann Oncol; 2005; 16 Suppl 2():ii229-32. PubMed ID: 15958463
    [No Abstract]   [Full Text] [Related]  

  • 9. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
    Pirker R; Minar W; Filipits M
    Clin Lung Cancer; 2008; 9 Suppl 3():S109-15. PubMed ID: 19419924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?
    Juergens R; Brahmer J
    Curr Oncol Rep; 2007 Jul; 9(4):255-64. PubMed ID: 17588349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gefitinib versus cetuximab in lung cancer: round one.
    Minna JD; Peyton MJ; Gazdar AF
    J Natl Cancer Inst; 2005 Aug; 97(16):1168-9. PubMed ID: 16106015
    [No Abstract]   [Full Text] [Related]  

  • 12. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
    Chung CH; Seeley EH; Roder H; Grigorieva J; Tsypin M; Roder J; Burtness BA; Argiris A; Forastiere AA; Gilbert J; Murphy B; Caprioli RM; Carbone DP; Cohen EE
    Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):358-65. PubMed ID: 20086114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of epidermal growth factor inhibitors.
    Toffoli G; De Mattia E; Cecchin E; Biason P; Masier S; Corona G
    Int J Biol Markers; 2007; 22(1 Suppl 4):S24-39. PubMed ID: 17520578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor as a target for chemotherapy.
    Vallbohmer D; Lenz HJ
    Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S19-27. PubMed ID: 15871762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
    Grünwald V; Hidalgo M
    J Natl Cancer Inst; 2003 Jun; 95(12):851-67. PubMed ID: 12813169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extending outcomes: epidermal growth factor receptor-targeted monoclonal antibodies in non-small-cell lung cancer.
    Joy AA; Butts CA
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S24-9. PubMed ID: 19362943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor inhibition and non-small cell lung cancer.
    von Eyben FE
    Crit Rev Clin Lab Sci; 2006; 43(4):291-323. PubMed ID: 16769595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
    Prahallad A; Sun C; Huang S; Di Nicolantonio F; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R
    Nature; 2012 Jan; 483(7387):100-3. PubMed ID: 22281684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.
    Ciardiello F; De Vita F; Orditura M; De Placido S; Tortora G
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):501-14. PubMed ID: 14662002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
    Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
    Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.